In a recent financial analysis, Barclays has adjusted its price target for Bruker Corporation (BRKR, Financial), lowering it from $60 to $50. Despite this reduction, the firm maintains an Overweight rating on the stock. This adjustment comes as part of a broader review of the life science tools and diagnostics sector ahead of the first quarter earnings reports.
Analyst Luke Sergott highlighted that while tools within this sector remain a defensive play, their defensive nature has diminished somewhat. This change is attributed to concerns about potential budget reductions linked to pharma-specific tariffs. These tariffs could pose new challenges for the sector as they might instigate further budget tightening.
In addition to the adjustment for Bruker, Barclays has taken a less optimistic view on the contract research organizations, downgrading them due to reduced visibility in the market.
